Balance between dopamine and serotonin release modulates behavioral effects of amphetamine-type drugs - PubMed (original) (raw)
Review
Balance between dopamine and serotonin release modulates behavioral effects of amphetamine-type drugs
Richard B Rothman et al. Ann N Y Acad Sci. 2006 Aug.
Abstract
The abuse of illicit stimulants is a worldwide crisis, yet few medicines are available for treating stimulant addiction. We have advocated the idea of "agonist therapy" for cocaine dependence. This strategy involves administration of stimulant-like medications (e.g., monoamine releasers) to alleviate cocaine withdrawal symptoms and prevent relapse. A chief limitation of this strategy is that many candidate medicines possess high abuse liability due to activation of mesolimbic dopamine (DA) neurons in reward pathways. Evidence suggests that serotonin (5-HT) neurons can provide an inhibitory influence over mesolimbic DA neurons. Thus, it might be predicted that the balance between DA and 5-HT transmission is a critical variable when developing medications with reduced stimulant side effects. In this article, we review recent studies from our laboratory that examined neurochemical and behavioral effects of a series of monoamine releasers which displayed different potencies at DA and 5-HT transporters. The data show that increasing 5-HT release can attenuate stimulant effects mediated by DA release, such as motor stimulation and drug self-administration. Our findings support the work of others and indicate that elevated synaptic 5-HT can dampen certain behavioral effects of DA-releasing agents. Moreover, the relationship between DA and 5-HT releasing potency is an important determinant in developing new agonist medications with reduced stimulant properties.
Similar articles
- Dual dopamine/serotonin releasers as potential medications for stimulant and alcohol addictions.
Rothman RB, Blough BE, Baumann MH. Rothman RB, et al. AAPS J. 2007 Jan 5;9(1):E1-10. doi: 10.1208/aapsj0901001. AAPS J. 2007. PMID: 17408232 Free PMC article. Review. - Development of a rationally designed, low abuse potential, biogenic amine releaser that suppresses cocaine self-administration.
Rothman RB, Blough BE, Woolverton WL, Anderson KG, Negus SS, Mello NK, Roth BL, Baumann MH. Rothman RB, et al. J Pharmacol Exp Ther. 2005 Jun;313(3):1361-9. doi: 10.1124/jpet.104.082503. Epub 2005 Mar 10. J Pharmacol Exp Ther. 2005. PMID: 15761112 - Dopamine/serotonin releasers as medications for stimulant addictions.
Rothman RB, Blough BE, Baumann MH. Rothman RB, et al. Prog Brain Res. 2008;172:385-406. doi: 10.1016/S0079-6123(08)00919-9. Prog Brain Res. 2008. PMID: 18772043 Review. - Dual dopamine/serotonin releasers: potential treatment agents for stimulant addiction.
Rothman RB, Blough BE, Baumann MH. Rothman RB, et al. Exp Clin Psychopharmacol. 2008 Dec;16(6):458-74. doi: 10.1037/a0014103. Exp Clin Psychopharmacol. 2008. PMID: 19086767 Free PMC article. Review.
Cited by
- 5-HT2C receptors in the nucleus accumbens constrain the rewarding effects of MDMA.
Pomrenze MB, Vaillancourt S, Salgado JS, Raymond KB, Llorach P, Touponse GC, Cardozo Pinto DF, Rastegar Z, Casey AB, Eshel N, Malenka RC, Heifets BD. Pomrenze MB, et al. bioRxiv [Preprint]. 2024 Oct 22:2024.10.20.619256. doi: 10.1101/2024.10.20.619256. bioRxiv. 2024. PMID: 39484424 Free PMC article. Preprint. - Locomotor stimulation produced by 3,4-methylenedioxymethamphetamine (MDMA) is correlated with dialysate levels of serotonin and dopamine in rat brain.
Baumann MH, Clark RD, Rothman RB. Baumann MH, et al. Pharmacol Biochem Behav. 2008 Aug;90(2):208-17. doi: 10.1016/j.pbb.2008.02.018. Epub 2008 Mar 4. Pharmacol Biochem Behav. 2008. PMID: 18403002 Free PMC article. - Overview of Movement Disorders Secondary to Drugs.
Rissardo JP, Vora N, Mathew B, Kashyap V, Muhammad S, Fornari Caprara AL. Rissardo JP, et al. Clin Pract. 2023 Aug 18;13(4):959-976. doi: 10.3390/clinpract13040087. Clin Pract. 2023. PMID: 37623268 Free PMC article. Review. - Critical role of the embryonic mid-hindbrain organizer in the behavioral response to amphetamine and methylphenidate.
Tilleman H, Kofman O, Nashelsky L, Livneh U, Roz N, Sillaber I, Biegon A, Rehavi M, Brodski C. Tilleman H, et al. Neuroscience. 2009 Nov 10;163(4):1012-23. doi: 10.1016/j.neuroscience.2009.07.040. Epub 2009 Jul 24. Neuroscience. 2009. PMID: 19635527 Free PMC article. - Behavioral, thermal and neurochemical effects of acute and chronic 3,4-methylenedioxymethamphetamine ("Ecstasy") self-administration.
Reveron ME, Maier EY, Duvauchelle CL. Reveron ME, et al. Behav Brain Res. 2010 Mar 5;207(2):500-7. doi: 10.1016/j.bbr.2009.10.038. Epub 2009 Nov 3. Behav Brain Res. 2010. PMID: 19891989 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical